
Please try another search
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Name | Age | Since | Title |
---|---|---|---|
Kyle Campbell | - | 2022 | Independent Director |
Howard A. Doss | 71 | 2025 | Director |
Edward J. Kimball | 61 | 2019 | Director & Member of Medical Advisory Board |
Morah Ibrahim | - | 2023 | Member of Medical Advisory Board |
Donald G. Fell | 79 | 2025 | Independent Director |
James K. Dzandu | - | 2022 | Member of Medical Advisory Board |
Surendra K. Ajjarapu | 54 | 2025 | Director |
Paul Montanarella | - | 2022 | Member of Medical Advisory Board |
Kraig T. Higginson | 69 | 2021 | Interim CEO, President & Executive Chairman of the Board |
Gary C. Bernard | - | 2023 | Member of Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review